Could a hot flash drug also protect your heart and memory?
NCT ID NCT07606664
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether fezolinetant, a drug for menopausal hot flashes and night sweats, also improves blood vessel function and memory. About 220 women aged 40–65 with moderate to severe symptoms will take either fezolinetant or a placebo daily for 12 weeks. Researchers will measure changes in artery health and cognitive performance to see if the drug offers benefits beyond symptom relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fezolinetant
What this could lead to
If it works, this could show that fezolinetant not only eases hot flashes but also protects blood vessels and memory during menopause.
What could go wrong
This is a Phase 3 trial, but it's still early to know if fezolinetant improves heart or brain health. The study is small and results may not apply to all women.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENOPAUSE HOT FLASHES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois, Chicago
Chicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••